[Treatment of membranous glomerulonephritis].
Forty-two patients with membranous glomerulonephritis were treated. Complete regression of the disease and nephrotic syndrome was attained in 46.3%, partial in 27.3% of all the cases of disease exacerbations. The importance of the individualized choice of the most efficacious drug therapy and promising results of the many-month treatment to raise the time of an ensuing remission are shown.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D002648:Child; D002738:Chloroquine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D011239:Prednisolone / Q000627:therapeutic use
D000925:Anticoagulants; D005938:Glucocorticoids; C023676:chloroquine diphosphate; D002738:Chloroquine; D003520:Cyclophosphamide; D011239:Prednisolone; D007213:Indomethacin
O lechenii membranoznogo glomerulonefrita.